10-K · February 25, 2026
Innoviva describes a strategic shift from a pure-play royalties business toward a diversified biopharmaceutical company focused on (1) maximizing respiratory royalties from GSK, (2) growing its Innoviva Specialty…
Earnings analysis · 10-Q
INVA earnings analysis
Filed May 6, 2026 · Our reading of the company's report
The latest report
Innoviva reported Q1 2026 revenue of $98.0 million, showing an 11% growth year-over-year, alongside a strong diluted EPS of $2.52, largely buoyed by a robust increase in net product sales. The company highlights…
Read full summary
Innoviva reported Q1 2026 revenue of $98.0 million, showing an 11% growth year-over-year, alongside a strong diluted EPS of $2.52, largely buoyed by a robust increase in net product sales. The company highlights significant gains in its operating income and strong performance within specific segments, particularly XACDURO® and GIAPREZA®.
Gross and operating margin
How much of each revenue dollar the business keeps.
One point per quarterly or annual filing. Both margins are shares of that report's revenue.
Where revenue came from
The business segments reported by the company.
Shares of the segments disclosed in this filing, largest first.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Reported figures
- Earnings per share
- $2.52
What stood out
-
11% Revenue Growth Year-over-Year
Total revenue for Q1 2026 reached $98.0 million, up from $88.6 million in Q1 2025.
-
Strong Diluted EPS Performance
Diluted EPS was reported at $2.52, a substantial increase from a net loss of $0.74 in Q1 2025.
-
Significant Growth in Net Product Sales
Net product sales grew to $41.4 million, representing a 37% increase from $30.3 million in the same quarter of the prior year.
-
Healthy Balance Sheet Position
Cash and cash equivalents stood at $603.1 million, showcasing a solid liquidity position.
-
Share Repurchase Program Confidence
Innoviva repurchased 971,066 shares for $20.4 million, reflecting strong confidence in the company’s intrinsic value.
-
Favorable Fair Value Changes in Investments
The changes in fair value of equity investments resulted in a net gain of $191.2 million, predominantly from Armata.
What to watch
-
Dependency on Royalty Revenue
Royalty revenue from GSK decreased to $55.2 million, down 5% from $57.8 million the previous year due to sales pressures.
-
Increase in Operating Expenses
SG&A expenses rose to $32.4 million in Q1 2026 from $27.5 million in Q1 2025, driven by promotional activities.
-
High Interest Expense Obligations
Interest expenses increased to $5.4 million in Q1 2026, compared to $4.7 million in Q1 2025, impacting profitability.
Management's outlook
Management maintains FY 2026 revenue guidance between $430 million and $460 million.
Earlier filings 4
10-Q · November 5, 2025
Innoviva reported Q3 2025 revenue of $107,800 (thousands) and diluted EPS of $1.08, driven by strong net product sales and large realized/unrealized investment fair value gains. Operating performance showed margin…
10-Q · August 6, 2025
Innoviva, Inc. reported a strong Q2 2025 with revenues of $100.283 million, slightly up from the $99.898 million reported a year ago, marking a 0.4% increase. Notably, diluted EPS surged to $0.77, significantly…
10-K · February 26, 2025
Innoviva positions itself as a royalties manager (respiratory royalties with GSK) plus an operating critical care & infectious disease platform (IST) anchored by four commercial products and a pipeline. The filing…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.